Celcuity is a cellular analysis company that is discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. We: identify the signaling dysfunction driving a patientâs cancer that genetic tests cannot detect; directly measure the effectiveness of a targeted therapy in patientâs living tumor cells; confirm the therapeutic matching the patientâs cancer driver is present and functional in the cells before prescribing treatment, striving to improve the likelihood of a positive clinical outcome. Source
No articles found.
Fresenius is a global healthcare group offering high-quality products and services...
Fresenius is a global healthcare group offering...
Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical comp...
Orchard Therapeutics is a fully integrated comm...
KemPharmÂŽ is a clinical-stage specialty pharmaceutical company engaged in the dis...
KemPharmÂŽ is a clinical-stage specialty pharma...
H&G Science aims to facilitate the safe and effective treatment of diseases. Our g...
H&G Science aims to facilitate the safe and eff...
LuminexÂŽ Corporation (NASDAQ: LMNX) develops, manufactures and markets proprietar...
LuminexÂŽ Corporation (NASDAQ: LMNX) develops, ...
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on deve...
Aptevo Therapeutics Inc. is a clinical-stage bi...
Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics and se...
Cancer Genetics, Inc. is an emerging leader in ...
InnaMed is developing a comprehensive care management platform. Our team is develo...
InnaMed is developing a comprehensive care mana...
At Delee were fundamentally changing not only the way cancer is detected but also...
At Delee were fundamentally changing not only ...
Autolus is a clinical-stage, biopharmaceutical company, focused on the development...
Autolus is a clinical-stage, biopharmaceutical ...
Join the National Investor Network and get the latest information with your interests in mind.